RxDoctor Payments Data

Michael Savona, MD

Internal Medicine · Wailuku, HINPI 1750430799

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. E.r. Squibb & Sons, L.L.C. accounts for 67.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in HI, where the typical reported total is $185.

$184in general payments, 2019–2025

Across 5 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$124
  • Novartis$60
$519,874in research payments, 2019–2025

Across 73 payments — averaging $7121.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$520K

What the payments were for

  • Food & beverage$184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.3$124
Novartis2$60

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$184 in reported general payments places this provider in the 45th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$5,538
Medicare patients
39
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$40,527
JanuviaSitagliptin Phosphate16$24,750
XareltoRivaroxaban18$17,087
Carvedilol ErCarvedilol Phosphate14$6,367
PremarinEstrogens, Conjugated14$4,312
Wixela InhubFluticasone Propion/Salmeterol22$3,915
Atorvastatin Calcium84$3,349
Raloxifene Hcl18$3,004
Lovastatin61$2,547
Felodipine ErFelodipine35$2,167
Amlodipine Besylate100$1,934
Metoprolol Succinate72$1,748
Losartan Potassium70$1,665
Metformin Hcl104$1,558
Tamsulosin Hcl58$1,356

Paid to pharmacies, not to this prescriber.

Other internal medicine in Wailuku

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →